Q1 EPS Forecast for Outlook Therapeutics Lowered by Analyst

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Equities research analysts at Brookline Capital Management cut their Q1 2025 EPS estimates for shares of Outlook Therapeutics in a research note issued to investors on Monday, December 30th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn ($0.70) per share for the quarter, down from their prior estimate of ($0.62). The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($3.84) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($2.00) EPS and FY2027 earnings at $1.26 EPS.

Several other research firms have also weighed in on OTLK. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research note on Friday, November 29th. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. Finally, BTIG Research cut their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.73.

Outlook Therapeutics Trading Up 1.6 %

OTLK stock opened at $1.89 on Wednesday. The stock’s 50 day simple moving average is $3.59 and its 200 day simple moving average is $5.77. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The firm has a market cap of $47.07 million, a P/E ratio of -0.18 and a beta of 0.46.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.06.

Institutional Investors Weigh In On Outlook Therapeutics

A number of hedge funds have recently made changes to their positions in OTLK. AQR Capital Management LLC bought a new position in Outlook Therapeutics in the 2nd quarter worth approximately $75,000. Christensen King & Associates Investment Services Inc. acquired a new position in Outlook Therapeutics during the 3rd quarter worth $55,000. Barclays PLC grew its stake in shares of Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock worth $111,000 after purchasing an additional 18,249 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Outlook Therapeutics during the second quarter valued at $232,000. Finally, XTX Topco Ltd bought a new stake in shares of Outlook Therapeutics during the third quarter valued at about $199,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.